O	0	6	Safety
O	7	9	of
B-intervention	10	21	bevacizumab
O	22	24	in
B-eligibility	25	35	metastatic
I-eligibility	36	42	breast
I-eligibility	43	49	cancer
I-eligibility	50	58	patients
I-eligibility	59	69	undergoing
I-eligibility	70	77	surgery
O	77	78	.

O	79	87	Evaluate
O	88	91	the
O	92	98	safety
O	99	101	of
O	102	109	surgery
O	110	112	in
O	113	121	relation
O	122	124	to
O	125	136	bevacizumab
O	137	139	in
O	140	143	the
O	144	149	first
O	149	150	-
O	150	154	line
O	155	164	treatment
O	165	167	of
O	168	178	metastatic
O	179	185	breast
O	186	192	cancer
O	193	194	(
O	194	197	mBC
O	197	198	)
O	199	201	in
O	202	205	two
O	206	219	international
O	220	226	trials
O	226	227	.

O	228	231	The
O	232	241	incidence
O	241	242	,
O	243	247	type
O	248	251	and
O	252	258	timing
O	259	261	of
O	262	266	post
O	266	267	-
O	267	275	surgical
O	276	284	bleeding
O	285	291	events
O	292	295	and
O	296	301	wound
O	301	302	-
O	302	309	healing
O	310	323	complications
O	324	328	were
O	329	337	assessed
O	338	340	in
O	341	349	surgical
O	350	358	patients
O	359	361	in
O	362	365	the
O	366	373	AVastin
O	374	377	And
O	378	387	DOcetaxel
O	388	389	(
O	389	394	AVADO
O	394	395	)
O	396	397	(
O	397	408	NCT00333775
O	408	409	)
O	410	413	and
O	414	421	Avastin
O	422	429	THErapy
O	430	433	for
O	434	442	advaNced
O	443	449	breAst
O	450	456	cancer
O	457	458	(
O	458	464	ATHENA
O	464	465	)
O	466	467	(
O	467	478	NCT00448591
O	478	479	)
O	480	486	trials
O	486	487	.

O	488	492	Both
O	493	498	study
O	499	508	protocols
O	509	517	followed
O	518	533	recommendations
O	534	536	to
O	537	545	withhold
O	546	557	bevacizumab
O	558	561	for
O	562	564	at
O	565	570	least
O	571	572	6
O	573	578	weeks
O	579	585	before
O	586	594	elective
O	595	602	surgery
O	603	606	and
O	607	609	to
O	610	614	wait
O	615	617	28
O	618	622	days
O	623	624	(
O	624	626	or
O	627	632	until
O	633	636	the
O	637	642	wound
O	643	646	was
O	647	652	fully
O	653	659	healed
O	659	660	)
O	661	666	after
O	667	672	major
O	673	680	surgery
O	681	687	before
O	688	700	recommencing
O	701	712	bevacizumab
O	713	720	therapy
O	720	721	.

O	722	724	In
O	725	730	AVADO
O	730	731	,
O	732	735	221
O	736	744	surgical
O	745	755	procedures
O	756	757	(
O	757	759	55
O	760	765	major
O	765	766	,
O	767	770	166
O	771	776	minor
O	776	777	)
O	778	782	were
O	783	792	performed
O	793	795	in
B-total-participants	796	799	155
O	800	808	patients
O	808	809	.

O	810	812	In
O	813	819	ATHENA
O	819	820	,
O	821	825	1190
O	826	834	surgical
O	835	845	procedures
O	846	847	(
O	847	850	435
O	851	856	major
O	856	857	,
O	858	861	755
O	862	867	minor
O	867	868	)
O	869	873	were
O	874	883	performed
O	884	886	in
B-total-participants	887	890	672
O	891	899	patients
O	899	900	.

O	901	904	One
O	905	916	bevacizumab
O	916	917	-
O	917	924	treated
O	925	930	AVADO
O	931	938	patient
O	939	940	(
B-iv-bin-percent	940	941	0
I-iv-bin-percent	941	942	.
I-iv-bin-percent	942	943	9
I-iv-bin-percent	943	944	%
O	944	945	)
O	946	949	who
O	950	959	underwent
O	960	967	surgery
O	968	979	experienced
O	980	981	a
B-outcome	982	987	grade
I-outcome	988	989	3
I-outcome	990	998	bleeding
I-outcome	999	1004	event
O	1004	1005	.

O	1006	1008	In
O	1009	1015	ATHENA
O	1015	1016	,
O	1017	1020	six
O	1021	1029	patients
O	1030	1031	(
B-iv-bin-percent	1031	1032	0
I-iv-bin-percent	1032	1033	.
I-iv-bin-percent	1033	1034	9
I-iv-bin-percent	1034	1035	%
O	1035	1036	)
O	1037	1040	who
O	1041	1050	underwent
O	1051	1058	surgery
O	1059	1070	experienced
B-outcome	1071	1076	grade
I-outcome	1077	1078	3
I-outcome	1079	1087	bleeding
I-outcome	1088	1094	events
O	1095	1098	and
B-iv-bin-abs	1099	1102	one
O	1103	1110	patient
O	1111	1112	(
B-iv-bin-percent	1112	1113	0
I-iv-bin-percent	1113	1114	.
I-iv-bin-percent	1114	1115	1
I-iv-bin-percent	1115	1116	%
O	1116	1117	)
O	1118	1129	experienced
O	1130	1131	a
B-outcome	1132	1137	grade
I-outcome	1138	1139	4
I-outcome	1140	1148	bleeding
I-outcome	1149	1154	event
O	1154	1155	.

O	1156	1158	No
B-outcome	1159	1164	grade
I-outcome	1165	1166	5
I-outcome	1167	1175	bleeding
I-outcome	1176	1182	events
O	1183	1185	in
O	1186	1194	patients
O	1195	1205	undergoing
O	1206	1213	surgery
O	1214	1218	were
O	1219	1227	reported
O	1228	1230	in
O	1231	1237	either
O	1238	1243	study
O	1243	1244	.

O	1245	1248	One
B-outcome	1249	1254	grade
I-outcome	1255	1256	3
I-outcome	1257	1262	wound
I-outcome	1262	1263	-
I-outcome	1263	1270	healing
I-outcome	1271	1283	complication
O	1284	1287	was
O	1288	1296	reported
O	1297	1299	in
O	1300	1304	each
O	1305	1307	of
O	1308	1311	the
O	1312	1317	AVADO
O	1318	1322	arms
O	1322	1323	:
B-control	1324	1331	placebo
O	1332	1333	(
O	1333	1334	n
O	1334	1335	=
B-cv-bin-abs	1335	1337	46
O	1337	1338	,
B-cv-bin-percent	1339	1340	2
I-cv-bin-percent	1340	1341	.
I-cv-bin-percent	1341	1342	2
I-cv-bin-percent	1342	1343	%
O	1343	1344	)
O	1344	1345	,
O	1346	1357	bevacizumab
O	1358	1359	7
O	1359	1360	.
O	1360	1363	5mg
O	1363	1364	/
O	1364	1366	kg
O	1367	1368	(
O	1368	1369	n
O	1369	1370	=
B-iv-bin-abs	1370	1372	57
O	1372	1373	,
B-iv-bin-percent	1374	1375	1
I-iv-bin-percent	1375	1376	.
I-iv-bin-percent	1376	1377	8
I-iv-bin-percent	1377	1378	%
O	1378	1379	)
O	1380	1383	and
O	1384	1395	bevacizumab
O	1396	1400	15mg
O	1400	1401	/
O	1401	1403	kg
O	1404	1405	(
O	1405	1406	n
O	1406	1407	=
B-iv-bin-abs	1407	1409	52
O	1409	1410	,
B-iv-bin-percent	1411	1412	1
I-iv-bin-percent	1412	1413	.
I-iv-bin-percent	1413	1414	9
I-iv-bin-percent	1414	1415	%
O	1415	1416	)
O	1416	1417	.

O	1418	1427	Incidence
O	1428	1430	of
B-outcome	1431	1436	grade
I-outcome	1437	1438	3
I-outcome	1438	1439	-
I-outcome	1439	1440	4
I-outcome	1441	1446	wound
I-outcome	1446	1447	-
I-outcome	1447	1454	healing
I-outcome	1455	1468	complications
O	1469	1471	in
O	1472	1478	ATHENA
O	1479	1482	was
B-iv-bin-percent	1483	1484	2
I-iv-bin-percent	1484	1485	.
I-iv-bin-percent	1485	1486	2
I-iv-bin-percent	1486	1487	%
O	1488	1491	and
B-iv-bin-percent	1492	1493	1
I-iv-bin-percent	1493	1494	.
I-iv-bin-percent	1494	1495	3
I-iv-bin-percent	1495	1496	%
O	1497	1499	in
O	1500	1508	patients
O	1509	1519	undergoing
O	1520	1525	minor
O	1526	1528	or
O	1529	1534	major
O	1535	1542	surgery
O	1542	1543	,
O	1544	1556	respectively
O	1556	1557	.

O	1558	1565	Surgery
O	1566	1569	can
O	1570	1572	be
O	1573	1582	performed
O	1583	1585	on
O	1586	1594	patients
O	1595	1599	with
O	1600	1603	mBC
O	1604	1614	undergoing
O	1615	1626	bevacizumab
O	1627	1634	therapy
O	1635	1639	with
O	1640	1641	a
O	1642	1645	low
O	1646	1650	risk
O	1651	1653	of
O	1654	1660	severe
O	1661	1669	bleeding
O	1670	1672	or
O	1673	1678	wound
O	1678	1679	-
O	1679	1686	healing
O	1687	1700	complications
O	1701	1705	post
O	1706	1713	surgery
O	1713	1714	,
O	1715	1717	if
O	1718	1725	current
O	1726	1735	labelling
O	1736	1751	recommendations
O	1752	1755	are
O	1756	1763	adhered
O	1764	1766	to
O	1766	1767	.
